237 related articles for article (PubMed ID: 35008510)
1. The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.
Seborova K; Kloudova-Spalenkova A; Koucka K; Holy P; Ehrlichova M; Wang C; Ojima I; Voleska I; Daniel P; Balusikova K; Jelinek M; Kovar J; Rob L; Hruda M; Mrhalova M; Soucek P; Vaclavikova R
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008510
[TBL] [Abstract][Full Text] [Related]
2. Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model.
Seborova K; Koucka K; Spalenkova A; Holy P; Ehrlichova M; Sychra T; Chen L; Bendale H; Ojima I; Sandoval-Acuña C; Truksa J; Soucek P; Vaclavikova R
Front Pharmacol; 2022; 13():971905. PubMed ID: 36438837
[TBL] [Abstract][Full Text] [Related]
3. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Ehrlichova M; Vaclavikova R; Ojima I; Pepe A; Kuznetsova LV; Chen J; Truksa J; Kovar J; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):95-105. PubMed ID: 16059735
[TBL] [Abstract][Full Text] [Related]
4.
Daniel P; Balušíková K; Václavíková R; Šeborová K; Ransdorfová Š; Valeriánová M; Wei L; Jelínek M; Tlapáková T; Fleischer T; Kristensen VN; Souček P; Ojima I; Kovář J
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833223
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
6. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
[TBL] [Abstract][Full Text] [Related]
7. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
O'Brien C; Cavet G; Pandita A; Hu X; Haydu L; Mohan S; Toy K; Rivers CS; Modrusan Z; Amler LC; Lackner MR
Cancer Res; 2008 Jul; 68(13):5380-9. PubMed ID: 18593940
[TBL] [Abstract][Full Text] [Related]
8. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
9. Resensitizing Paclitaxel-Resistant Ovarian Cancer via Targeting Lipid Metabolism Key Enzymes CPT1A, SCD and FASN.
Ma Q; Liu Z; Wang T; Zhao P; Liu M; Wang Y; Zhao W; Yuan Y; Li S
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003694
[TBL] [Abstract][Full Text] [Related]
10.
Jeleniewicz W; Cybulski M; Nowakowski A; Stenzel-Bembenek A; Guz M; Marzec-Kotarska B; Kotarski J; Stepulak A
Anticancer Res; 2019 Apr; 39(4):1821-1827. PubMed ID: 30952722
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
13. TRIP6 accelerates the proliferation and invasion of cervical cancer by upregulating oncogenic YAP signaling.
Yang F; Li L; Zhang J; Zhang J; Yang L
Exp Cell Res; 2020 Nov; 396(1):112248. PubMed ID: 32853630
[TBL] [Abstract][Full Text] [Related]
14. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.
Boyerinas B; Park SM; Murmann AE; Gwin K; Montag AG; Zillhardt M; Hua YJ; Lengyel E; Peter ME
Int J Cancer; 2012 Apr; 130(8):1787-97. PubMed ID: 21618519
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
16. TRIP6 regulates p27 KIP1 to promote tumorigenesis.
Lin VT; Lin VY; Lai YJ; Chen CS; Liu K; Lin WC; Lin FT
Mol Cell Biol; 2013 Apr; 33(7):1394-409. PubMed ID: 23339869
[TBL] [Abstract][Full Text] [Related]
17. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
[TBL] [Abstract][Full Text] [Related]
18. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
Petrangolini G; Cassinelli G; Pratesi G; Tortoreto M; Favini E; Supino R; Lanzi C; Belluco S; Zunino F
Br J Cancer; 2004 Apr; 90(7):1464-8. PubMed ID: 15054472
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
20. Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel.
Daniel P; Halada P; Jelínek M; Balušíková K; Kovář J
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31248089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
